Helgi van de Velde
Overview
Explore the profile of Helgi van de Velde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
4665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richardson P, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, et al.
Blood Cancer J
. 2024 Nov;
14(1):209.
PMID: 39609425
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The...
2.
Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A, et al.
Exp Hematol Oncol
. 2024 Nov;
13(1):114.
PMID: 39538354
Despite therapeutic advancements, multiple myeloma (MM) remains incurable. NK cells have emerged as a promising option for the treatment of MM. NK cells are heterogenous and typically classified based on...
3.
Zabaleta A, Blanco L, Kim P, Bisht K, Wang H, van de Velde H, et al.
Br J Haematol
. 2024 Sep;
205(6):2262-2267.
PMID: 39308023
There is accumulating evidence of BCMA and GPRC5D loss after treatment with T-cell redirecting therapies in patients with relapsed/refractory multiple myeloma (RRMM). While complete CD38 loss is not observed upon...
4.
Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos M, et al.
Eur J Haematol
. 2024 Jul;
113(5):593-605.
PMID: 38993150
Objectives: Cluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi-centre, Phase 1, single-agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)-modified anti-CD38...
5.
Martin-Sanchez E, Blanco L, Kim P, Bisht K, Wang H, van de Velde H, et al.
Blood Adv
. 2024 May;
8(15):3875-3879.
PMID: 38815228
No abstract available.
6.
Grab A, Kim P, John L, Bisht K, Wang H, Baumann A, et al.
Cells
. 2024 May;
13(10.
PMID: 38786100
Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and...
7.
Keller A, Reiman L, Perez de Acha O, Parzych S, Forsberg P, Kim P, et al.
Cancer Res Commun
. 2024 Feb;
4(3):757-764.
PMID: 38421887
Significance: This study introduces the use of My-DST to measure and characterize sensitivity to anti-CD38 T-cell engager SAR442257 in primary samples using matched endogenous T cells. Preclinical testing in samples...
8.
Bisht K, Fukao T, Chiron M, Richardson P, Atanackovic D, Chini E, et al.
Cancer Med
. 2023 Oct;
12(20):20332-20352.
PMID: 37840445
Background: CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved-daratumumab and isatuximab. CD38 is an ectoenzyme that degrades...
9.
Lesokhin A, LeBlanc R, Dimopoulos M, Capra M, Carlo-Stella C, Karlin L, et al.
Cancer Med
. 2023 Mar;
12(9):10254-10266.
PMID: 36866838
Background: Given the incurable nature of multiple myeloma (MM), efforts are made to improve the efficacy of anti-CD38 monoclonal antibodies via combinations with other potentially synergistic therapies. This Phase 1/2...
10.
Beksac M, Spicka I, Hajek R, Bringhen S, Jelinek T, Martin T, et al.
Leuk Res
. 2022 Sep;
122:106948.
PMID: 36108425
The Phase 3 ICARIA-MM (NCT02990338) and IKEMA (NCT03275285) studies demonstrated that isatuximab (Isa) plus pomalidomide (P) and dexamethasone (d; Isa-Pd) or carfilzomib (K) and d (Isa-Kd) improved progression-free survival (PFS)...